The Hong Kong Centre for Novostics is reportedly developing a lower-cost version of the ‘Galleri test,’ a highly accurate universal cancer blood test. According to Professor K.C Allen Chan, the inexpensive version will only cost $50, a significant price drop from the current $1,000 price tag.
The test works by identifying a signal shared by multiple cancer types, allowing for early detection and potentially life-saving intervention. In a trial involving over 5000 patients, the ‘Galleri test’ correctly identified two-thirds of cancerous tumors, and can detect over 50 forms of cancer with a single blood draw. This early detection could significantly increase the survival rate for patients.
However, the ‘Galleri test’ and its parent company ‘Grail’ faced controversy when nearly 400 clients received erroneous notifications of potential cancer diagnosis. The company attributed the mistake to a “software configuration issue” and stated that it did not reflect the accuracy of the test findings.
Despite this setback, the development of a more affordable version of the ‘Galleri test’ represents a significant advancement in cancer diagnostic technology. With continued improvements, including a second-generation model expected to cost only $200, the test has the potential to revolutionize cancer detection and treatment.
I have over 10 years of experience in the cryptocurrency industry and I have been on the list of the top authors on LinkedIn for the past 5 years. I have a wealth of knowledge to share with my readers, and my goal is to help them navigate the ever-changing world of cryptocurrencies.
